← Back to Search

PRIME intervention for Leukemia (DISCOVERY Trial)

N/A
Waitlist Available
Led By Daniel R Richardson, MD, MA, MSc
Research Sponsored by UNC Lineberger Comprehensive Cancer Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 24 months
Awards & highlights

DISCOVERY Trial Summary

This trial aims to determine if a new decision support tool called PRIME can help improve patient-doctor agreement on treatment decisions by providing personalized feedback based on the patient's values and preferences.

Who is the study for?
This trial is for adults aged 60 or older who are new to the hematology/oncology clinic and need treatment decisions for conditions like lymphoma, leukemia, or multiple myeloma. Participants must be able to understand the study and give consent.Check my eligibility
What is being tested?
The DISCOVERY trial is testing PRIME, a decision support tool designed to help patients with blood cancers make treatment choices that align with their personal values by providing feedback to both patients and doctors.See study design
What are the potential side effects?
Since PRIME is a decision support tool rather than a medication, it does not have physical side effects. However, participants may experience emotional or psychological impacts from discussing their values and preferences.

DISCOVERY Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 24 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 24 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Difference in COLLABORATE scores between arms
Secondary outcome measures
Difference in COLLABORATE scores between arms in a subgroup of patients

DISCOVERY Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: PRIME interventionExperimental Treatment1 Intervention
Receive the PRIME intervention.
Group II: Usual CareActive Control1 Intervention
Receive usual care.

Find a Location

Who is running the clinical trial?

UNC Lineberger Comprehensive Cancer CenterLead Sponsor
351 Previous Clinical Trials
87,832 Total Patients Enrolled
18 Trials studying Leukemia
18,608 Patients Enrolled for Leukemia
Daniel R Richardson, MD, MA, MScPrincipal InvestigatorUNC Lineberger Comprehensive Cancer Center

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is the enrollment phase of this medical study currently accepting participants?

"As per clinicaltrials.gov, the specified medical trial is presently not open for recruitment. Originally listed on 4th January 2024 and last updated on 28th February 2024, it is currently inactive. However, amidst a pool of 3672 other trials seeking participants, this study stands out as temporarily closed to enlistment."

Answered by AI
~333 spots leftby Apr 2025